Insider buying last 90 days
No open-market insider purchases were filed for ARQT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ARQT insider filing, plotted on the chart in Gekko.Open ARQT in Gekko
NASDAQ: ARQT
Arcutis Biotherapeutics (ARQT) Stock Analysis & Forecast
Oct 12 close
$26.22−0.36 (−1.4%)
Gekko Brief
AI summaryOct 12 closeThis week Arcutis Biotherapeutics drew attention mainly around its ZORYVE franchise. The company presented fresh clinical and real-world data at EADV and Fall Clinical, including findings from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% for infants. ZORYVE cream 0.15% also won Marie Claire's inaugural Best Prescription Skin Solution Award for its use in mild to moderate atopic dermatitis. On the analyst side, Argus issued a "HOLD" rating, lowering its target price to $23.00 from a prior price of $26.58, while the broader consensus among 6 firms remains at 6 buy ratings with a consensus target of 37 and consensus upside of 41.1%.
ARQT closed at $26.22, down 1.4% on the day, with the close sitting above both the 50-day average of $25.38 and the 200-day average of $25.10. Shares have returned 9.8% over one month and 26.6% over one year, though the 3-month return is -2.2%. The GekkoIndex reads 56.6, placing the stock in the Neutral zone. Price remains 12.7% below Gekko Fair Value of $30.03.
The next 20 trading days bring Arcutis' earnings report on 27 October, after the close, only 15 days away, which falls inside a typical holding window and has produced an average absolute reaction of 10.7% historically. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality for this stretch of the calendar has averaged -6.8% over 5 years, rising in only 2 of them, a pattern worth noting alongside the upcoming earnings date.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Arcutis Biotherapeutics price vs fair value
Close $26.22200-day averageGekko Fair Value $30.03
Arcutis Biotherapeutics quick facts
- Market cap
- $3.28B
- P/E ratio
- 111.3
- Forward P/E
- 26.4
- EPS, TTM
- $0.22
- Revenue, TTM
- $464.0M
- Profit margin
- 6.2%
- Dividend yield
- —
- Beta
- 1.58
- Volume
- 1.54M avg 3.35M
- 1-year return
- +26.6%
- Typical daily move
- ±4.8%
- Typical 20-day move
- ±11.7%
- 50-day average
- $25.38
- 200-day average
- $25.10
- Next earnings
- Oct 27 after close
- Shares outstanding
- 125.7M
Arcutis Biotherapeutics swing-trade checklist
Arcutis Biotherapeutics scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $26.22 is above the 50-day ($25.38) and 200-day ($25.10) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
56.6, Neutral
Reading 56.6 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
12.7% below
Price is 12.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 15 days
Reports on Oct 27, 2026, 15 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−6.8% on average
From this point in the calendar, the next 20 trading days averaged −6.8% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Arcutis Biotherapeutics stock chart and price history
Arcutis Biotherapeutics closed at $26.22 on Oct 12, 2026, +26.6% over the past year, inside a 52-week range of $19.30 to $31.77.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +9.8%
- 3 months
- −2.2%
- 6 months
- +8.7%
- 1 year
- +26.6%
The full ARQT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ARQT in Gekko
Follow Arcutis Biotherapeutics through every session
Put ARQT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ARQT in GekkoFree for 7 days. No credit card required.
About Arcutis Biotherapeutics
Arcutis Biotherapeutics works on medicines for conditions that affect the skin, bringing treatments through development toward the market rather than selling consumer products directly. Its best-known program centers on a topical roflumilast cream studied for plaque psoriasis and atopic dermatitis, which has finished later-stage clinical testing. The company is largely defined by this work in dermatology-focused drug development.
Beyond that lead candidate, Arcutis maintains a broader set of experimental treatments. These include a roflumilast foam being studied for seborrheic dermatitis and scalp psoriasis, a topical JAK1 inhibitor aimed at hand eczema and vitiligo, and a related compound formulated for deeper skin penetration that is being looked at for alopecia areata. This spread of candidates reflects a focus on multiple inflammatory and immune-related skin conditions rather than a single disease area.
The company was founded in 2016, originally under the name Arcutis, Inc., before adopting its current name in October 2019. It is headquartered in Westlake Village, California, and its shares are listed on the NASDAQ under the ticker ARQT.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- arcutis.com
Arcutis Biotherapeutics GekkoIndex: the smart money zone
Arcutis Biotherapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 56.6, in the Neutral zone, down 1.2 points over five sessions.
56.6Neutral
Down 1.2 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 7 | Too few readings yet | |||
| Accumulation | 207 | +3.1% | +8.2% | ||
| Neutral (current zone) | 417 | +0.5% | +2.2% | ||
| Distribution | 40 | +5.9% | +21.5% | ||
| Selling | 11 | Not available | |||
Average ARQT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the ARQT price, zone by zone.Track ARQT in Gekko
Is Arcutis Biotherapeutics stock overvalued? Gekko Fair Value
Arcutis Biotherapeutics trades 12.7% below Gekko Fair Value of $30.03, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Arcutis Biotherapeutics shares are worth, recalculated every trading day.
$30.03
Gekko Fair Value, Oct 10, 2026
12.7% Undervalued
At the end of Aug 2026 the price was 28.0% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ARQT in Gekko
Arcutis Biotherapeutics insider and Congress trading
No open-market insider purchases were filed for Arcutis Biotherapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ARQT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ARQT, plotted on the chart in Gekko.Open ARQT in Gekko
Arcutis Biotherapeutics earnings: next date and track record
Arcutis Biotherapeutics reports on Oct 27, 2026, after the close (15 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Oct 27, 2026
Expected after the close, 15 days away
- EPS estimate
- $0.18
- Revenue estimate
- $141.9M
7 of 8reports beat the EPS estimate
±10.7%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- Arcutis reported Q2 2026 results highlighting continued growth of its ZORYVE franchise, which received its seventh FDA approval in four years—ZORYVE cream 0.3% for plaque psoriasis in children as young as age 2. The FDA accepted an sNDA for ZORYVE cream 0.05% for atopic dermatitis in infants down to 3 months, with a PDUFA date of February 23, 2027. The company is reinvesting capital generated from its growing inline business into pipeline expansion and patient access innovation, including a virtual health platform and AI-enabled patient access tools.
- Guidance
- Management expects continued ZORYVE revenue growth supporting reinvestment into pipeline and patient access initiatives. A key near-term catalyst is the February 23, 2027 PDUFA date for ZORYVE cream 0.05% in infants with atopic dermatitis, which could expand the addressable market further.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $0.11 est $0.06 | $129.9M est $118.9M | +1.5% |
| May 6, 2026 | −$0.09 est −$0.02 | $105.4M est $103.7M | −11.8% |
| Feb 25, 2026 | $0.13 est $0.03 | $129.5M est $113.1M | +5.9% |
| Oct 28, 2025 | $0.06 est −$0.09 | $99.22M est $110.8M | +28.8% |
| Aug 6, 2025 | −$0.13 est −$0.18 | $81.50M est $80.63M | −7.9% |
| May 6, 2025 | −$0.20 est −$0.21 | $65.85M est $72.70M | −11.1% |
| Feb 25, 2025 | −$0.09 est −$0.26 | $71.36M est $60.52M | +6.7% |
| Nov 6, 2024 | −$0.33 est −$0.42 | $44.76M est $37.62M | +11.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Arcutis Biotherapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Arcutis Biotherapeutics is $37.00, +41.1% from the last close, from 6 firms rating the stock in the last 90 days.
$37.00consensus 12-month target, +41.1% from the last close
Now $26.22Avg $37.00
Low $34High $40
Each firm’s latest rating in the last 90 days: 6 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 10 | H.C. Wainwright | $34 | +29.7% |
| Aug 6 | H.C. Wainwright | $34 | +29.7% |
| Aug 6 | Morgan Stanley | $38 | +44.9% |
| Aug 6 | Needham | $40 | +52.6% |
| Aug 6 | Mizuho Securities | $36 | +37.3% |
+2.2%average 20-day move after past Neutral readings
−6.8%average move over the next 20 trading days in the last 5 years
±4.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Arcutis Biotherapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Arcutis Biotherapeutics averaged −6.8% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.6% | 2 of 5 |
| Next 10 trading days | −15.6% | 1 of 5 |
| Next 15 trading days | −8.5% | 2 of 5 |
| Next 20 trading days | −6.8% | 2 of 5 |
| Next 30 trading days | −7.3% | 2 of 5 |
For scale, ARQT’s typical 20-trading-day move in either direction is about 11.7%.
Arcutis Biotherapeutics market cap and key statistics
Arcutis Biotherapeutics’s market cap is $3.28B, with a P/E ratio of 111.3 and revenue of $464.0M over the last twelve months.
Valuation
- Market cap
- $3.28B
- P/E ratio
- 111.3
- Forward P/E
- 26.4
- EPS, TTM
- $0.22
- Gekko Fair Value
- $30.03
Trading
- Volume
- 1.54M
- Avg volume, 20 days
- 3.35M
- 52-week high
- $31.77
- 52-week low
- $19.30
- Shares outstanding
- 125.7M
Financials
- Revenue, TTM
- $464.0M
- Profit margin
- 6.2%
- Return on equity
- 15.9%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.58
- Typical daily move
- ±4.8%
- Typical 20-day move
- ±11.7%
Arcutis Biotherapeutics stock news this week
Coverage of Arcutis Biotherapeutics this week reads positive: 2 positive, 1 neutral and 1 negative headlines.
- Arcutis Biotherapeutics, Inc. (ARQT) Stock ForecastsYahoo! Finance Canada, Oct 11
- Arcutis Biotherapeutics (ARQT) Showcased Fresh ZORYVE Data, Is It Still 28% Below Fair Value?Yahoo Finance UK, Oct 10
- Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall ClinicalGlobeNewsWire, Oct 9
- Arcutis Biotherapeutics’ ZORYVE Cream 0.15% Wins Marie Claire’s Inaugural Best Prescription Skin Solution AwardQuiver Quantitative, Oct 6
- Arcutis' ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty AwardGlobeNewsWire, Oct 6
- An iShares ETF has an interest above 5% in Arcutis (ARQT), where BlackRock reports a passive stake.Stock Titan, Oct 5
Arcutis Biotherapeutics peers
Arcutis Biotherapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Arcutis Biotherapeutics stock FAQ
What is Arcutis Biotherapeutics’s market cap?
Arcutis Biotherapeutics’s market cap is $3.28B at the Oct 12, 2026 close of $26.22, with 125.7M shares outstanding. The shares trade on a P/E ratio of 111.3.
What is the Arcutis Biotherapeutics stock forecast?
The consensus analyst 12-month price target for Arcutis Biotherapeutics is $37.00, +41.1% from the last close. Of the 6 firms that rated the stock in the last 90 days, 6 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Arcutis Biotherapeutics stock overvalued or undervalued?
On Gekko’s estimate Arcutis Biotherapeutics is undervalued: the Oct 12, 2026 close of $26.22 is 12.7% below Gekko Fair Value of $30.03. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Arcutis Biotherapeutics report earnings next?
Arcutis Biotherapeutics is expected to report on Oct 27, 2026, after the market closes (15 days away). Analysts expect earnings of $0.18 per share on revenue of $141.9M. Arcutis Biotherapeutics beat the earnings estimate in 7 of its last 8 reports, moving 10.7% on average across the report.
What is Arcutis Biotherapeutics’s 52-week high and low?
Arcutis Biotherapeutics’s 52-week high is $31.77 and its 52-week low is $19.30; it closed at $26.22 on Oct 12, 2026, +26.6% over the past year.
Is Arcutis Biotherapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and fair value), 1 as mixed (gekkoindex) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Arcutis Biotherapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.